Industry leader Geoff Mackay to Chair board of Satellos Bioscience
TORONTO--(BUSINESS WIRE)--Sep 17, 2018--Drug development start-up Satellos Bioscience has announced that regenerative medicine industry leader Geoff Mackay is joining its board of directors as Chair, effective immediately.
Mackay brings a wealth of relevant experience to Satellos, with specific senior business background in regenerative bioscience. He is currently President and CEO of gene therapy company AVROBIO and was the founding CEO of eGenesis, applying CRISPR Cas-9 gene editing to xenotransplantation.
Satellos is a seed-stage regenerative medicine company focused on development of proprietary drugs to stimulate tissue regeneration by re-establishing normal stem-cell polarity. Polarity is the process by which stem cells balance between replenishing themselves and producing specialized tissue cells. Satellos’ platform is based on pivotal work by scientific founder Dr. Michael Rudnicki, Director of Regenerative Medicine at the Ottawa Hospital Research Institute. Dr. Rudnicki has demonstrated that polarity can be modulated, and that it is relevant to a range of serious diseases, such as Duchenne muscular dystrophy.
Geoff Mackay said of his decision to take on his role at Satellos, “I am impressed by the founders of Satellos and excited by the originality and relevance of the company’s scientific approach. I believe this team can make an important contribution to regenerative medicine and to patients, and I am looking forward to working with them.”
Mackay is noted for his tenure as CEO of Organogenesis Inc., where he steered the company through the treatment of more than 1 million patients and annual revenue of over $150M. He previously held senior global positions at Novartis and has served as Chair of the Board for MassBio as well as the Alliance for Regenerative Medicine. Geoff is also a past member of the advisory council to the Health Policy Commission of the Commonwealth of Massachusetts.
Frank Gleeson, Satellos co-founder, says Mackay’s arrival at Satellos is a coup for the innovative start-up, “We are very pleased to welcome Geoff to the Board and look forward to his leadership as Chair. His knowledge, networks and expertise in developing novel technologies and building companies in the regenerative medicine space will be invaluable to Satellos.”
ABOUT SATELLOS BIOSCIENCE INC.
Satellos is a regenerative medicine company based in Canada. It was co-founded in 2018 by leading stem cell scientist Dr. Michael Rudnicki and biotech entrepreneur Frank Gleeson in partnership with a unit of Bloom-Burton & Co, Canada’s premier healthcare investment bank. The company is focused on developing small molecule therapeutics to stimulate intrinsic tissue regeneration by modulating stem-cell polarity — a process that balances replenishment of stem cells and production of specialized tissue cells. Satellos’ platform is based on seminal research by Dr. Rudnicki that demonstrated the contribution of dysregulated stem cell polarity to disease and the ability of small molecule drugs to correct the imbalance. Satellos is currently focused on advancing its novel approach for the treatment of Duchenne muscular dystrophy, and multiple additional skeletomuscular and neuronal diseases.
View source version on businesswire.com:https://www.businesswire.com/news/home/20180917005110/en/
CONTACT: Satellos BioScience
Frank Gleeson, 1.905.336.6128
Founder and CEO
KEYWORD: NORTH AMERICA CANADA
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY
SOURCE: Satellos BioScience Inc.
Copyright Business Wire 2018.
PUB: 09/17/2018 08:00 AM/DISC: 09/17/2018 08:01 AM